HB 907 creates the Florida Institute for Pediatric Rare Diseases within the Florida State University College of Medicine and gives it a statewide mission to improve diagnosis, treatment, research, education, and advocacy for children with rare diseases. The institute is directed to build clinical and research capacity, develop better diagnostic and genetic screening tools, train health professionals, and collaborate with universities, hospitals, advocacy groups, and government agencies.
The bill also establishes the Sunshine Genetics Pilot Program, a five-year opt-in newborn genetic screening program that may include whole genome sequencing. Parents must consent for participation, and screening results must be shared with the newborn’s parent and health care practitioner. The institute must maintain a secure database for program data, provide deidentified data to consortium members under data-sharing agreements, and submit a report by December 1, 2030, on enrollment, sequencing, clinical and public health impact, and cost effectiveness.
In addition, the bill creates the Sunshine Genetics Consortium to coordinate research and precision medicine efforts across state universities, children’s hospitals, and industry partners. The consortium is tasked with advancing genomic sequencing, artificial intelligence applications in genomics, clinician education, workforce development for geneticists, fundraising from private and nonprofit sources, and reporting on use of deidentified newborn data. An oversight board with representatives from universities, Nicklaus Children’s Hospital, and legislative and executive appointees will administer the consortium and meet at least twice a year.
The bill changes state law by adding a new section to the Florida Statutes and by creating a new state-supported research and clinical infrastructure centered at FSU. Its implementation is expressly contingent on available appropriations in the General Appropriations Act, meaning funding will determine how fully the institute, pilot program, and consortium operate. The act takes effect July 1, 2025.
The available record shows no committee transcript excerpts or recorded votes, so there is no documented floor or committee debate in the provided materials. Based on the bill’s final enactment, the overall sentiment appears favorable and supportive, with the Legislature ultimately approving a major investment in pediatric rare disease research and newborn genomic screening. Any likely concerns would center on privacy, consent, data security, and the use of whole genome sequencing in newborns, but those issues are not reflected in the provided discussion record.
HB 907 creates new statutory authority in chapter 1004, Florida Statutes, establishing the Florida Institute for Pediatric Rare Diseases at Florida State University College of Medicine and authorizing the Sunshine Genetics Pilot Program and Sunshine Genetics Consortium. It directs the institute to conduct research, provide clinical services, train professionals, manage a secure newborn genomics database, and share deidentified data under agreements, while also creating an oversight structure with university, hospital, and legislative/executive representation. The bill affects newborn screening, pediatric rare disease research, precision medicine, genetic counseling, data governance, and state-university collaboration, but its provisions are contingent on annual appropriations.
No committee transcripts or vote tallies were provided, so there is no direct record of debate or opposition in the materials supplied. The bill’s final status as enacted chapter law suggests broad legislative support for expanding pediatric rare disease research and newborn genetic screening in Florida. The tone of the measure is policy-forward and innovation-oriented, emphasizing research, clinical care, and collaboration rather than controversy.
The text itself suggests several potential areas of concern: informed parental consent for an opt-in newborn screening program, privacy and security of genomic data, the release and sharing of deidentified newborn data, and the use of whole genome sequencing in a state-run pilot. The bill also depends on available funding, which can create practical contention over appropriations and implementation priorities. However, the provided record contains no transcript or vote evidence identifying specific lawmakers, stakeholders, or organized opposition.